Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recent developments in chemotherapy for bladder cancer.

D J Vaughn¹, S B Malkowicz

¹Department of Medicine Hematology-Oncology Division, University of Pennsylvania School of Medicine, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA.

Oncology (Williston Park, N.Y.)

|June 30, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

A method to improve reconstruction of the distribution of hemoglobin, oxygenation, and MLu concentration in the human prostate before and after photodynamic therapy.

Proceedings of SPIE--the International Society for Optical Engineering·2015

Same author

A heterogeneous algorithm for PDT dose optimization for prostate.

Proceedings of SPIE--the International Society for Optical Engineering·2015

Same author

Steady state expression of cell-cycle regulatory genes in prostate carcinoma cell lines.

Urologic oncology·2011

Same author

Sleep and daily functioning during androgen deprivation therapy for prostate cancer.

European journal of cancer care·2010

Chemotherapy, including cisplatin, gemcitabine, and paclitaxel, offers options for invasive bladder cancer. Ongoing trials investigate new agents and biomarkers for improved patient outcomes.

Area of Science:

Oncology
Medical Chemistry

Background:

Invasive bladder cancer is sensitive to chemotherapy.
Cisplatin-based chemotherapy has historically improved outcomes for metastatic disease.
New agents like gemcitabine and paclitaxel provide additional treatment options.

Purpose of the Study:

To review current chemotherapy options for invasive bladder cancer.
To highlight ongoing research in neoadjuvant and adjuvant settings.
To explore the use of prognostic biomarkers in clinical trials.

Main Methods:

Review of historical and recent advancements in chemotherapy for bladder cancer.
Discussion of ongoing randomized trials comparing different chemotherapy regimens.
Exploration of the role of biological markers in risk stratification.

Related Experiment Videos

Main Results:

Cisplatin-based chemotherapy is a cornerstone for metastatic bladder cancer.
Gemcitabine and paclitaxel represent newer therapeutic options.
Research is actively exploring neoadjuvant/adjuvant chemotherapy and biomarkers.

Conclusions:

Chemotherapy remains crucial for invasive bladder cancer management.
Newer agents and treatment strategies are expanding therapeutic possibilities.
Prognostic biomarkers hold promise for personalized treatment approaches.